




Instance: composition-en-c2d0e28fbe1723337dab22fe407d0234
InstanceOf: CompositionUvEpi
Title: "Composition for brukinsa Package Leaflet"
Description:  "Composition for brukinsa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp24f578d462a457567344326b7c54ba53)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - brukinsa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What BRUKINSA is and what it is used for </li>
<li>What you need to know before you take BRUKINSA </li>
<li>How to take BRUKINSA </li>
<li>Possible side effects </li>
<li>How to store BRUKINSA </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What brukinsa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What brukinsa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>BRUKINSA is an anticancer medicine that contains the active substance zanubrutinib. It belongs to a 
class of medicines called protein kinase inhibitors. This medicine works by blocking Bruton's tyrosine 
kinase, a protein in the body that helps cancer cells grow and survive. By blocking this protein, 
BRUKINSA reduces the number of cancer cells and slows down the worsening of the cancer. </p>
<p>BRUKINSA is used to treat Waldenstr m s macroglobulinaemia (also known as lymphoplasmacytic 
lymphoma), a cancer affecting a type of white blood cells called B lymphocytes or B cells that make 
too much of a protein called IgM. This medicine is used when the disease has come back, or treatment 
has not worked or in patients who cannot have chemotherapy together with an antibody. </p>
<p>BRUKINSA is also used to treat marginal zone lymphoma. This is a type of cancer that also affects B 
lymphocytes or B cells. In marginal zone lymphoma, the abnormal B cells multiply too quickly and 
live for too long. This may cause enlargement of organs that are part of body s natural defences such 
as lymph node and spleen. The abnormal B cells may also affect various organs, such as stomach, 
salivary gland, thyroid, eyes, lungs, bone marrow and blood. Patients may have fever, weight loss, 
tiredness and night sweats, but also symptoms that depend on where the lymphoma develop. This 
medicine is used when the disease has come back, or treatment has not worked.  </p>
<p>BRUKINSA is also used to treat chronic lymphocytic leukaemia (CLL), another type of cancer 
affecting B cells that involves the lymph nodes. This medicine is used in patients who have not 
previously been treated for CLL or when the disease has come back or has not responded to previous 
treatment. 
BRUKINSA is also used to treat follicular lymphoma (FL). FL is a slow growing cancer that affects 
the B lymphocytes. When you have FL, you have too many of these B lymphocytes in your lymph 
nodes, spleen, and bone marrow. BRUKINSA is taken together with another medicine called 
 obinutuzumab  when the disease has come back or when previously used medicines have not been 
effective. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take BRUKINSA  </p>
<ul>
<li>if you are allergic to zanubrutinib or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions  </p>
<p>Talk to your doctor, pharmacist or nurse before taking BRUKINSA: 
* if you have ever had unusual bruising or bleeding or are on any medicines or supplements that 
increase your risk of bleeding (see section  Other medicines and BRUKINSA ). If you have 
had recent surgery or plan to have surgery, your doctor may ask you to stop taking 
BRUKINSA for a short time (3 to 7 days) before and after your surgery or dental procedure 
* if you have an irregular heartbeat or have a history of irregular heartbeat or severe heart 
failure, or if you have any of the following: shortness of breath, weakness, dizziness, light-
headedness, fainting or near fainting, chest pain or swollen legs 
* if you have ever been advised that you are at higher risk of infections. You may experience 
viral, bacterial, or fungal infections during treatment with BRUKINSA with the following 
possible symptoms: fever, chills, weakness, confusion, body aches, cold or flu symptoms, feel 
tired or feel short of breath, yellowing of the skin or eyes (jaundice). 
* if you have ever had or might have hepatitis B. This is because BRUKINSA could cause 
hepatitis B to become active again. Patients will be carefully checked by their doctor for signs 
of this infection before treatment is started 
* if you have liver or kidney problems 
* if you have recently had any surgery, especially if it might affect how you absorb food or 
medicines from your stomach or gut 
* if you recently had low counts of red blood cells, infection-fighting cells or platelets in your 
blood 
* if you had other carcinomas in the past including skin cancer (e.g., basal cell carcinoma or 
squamous cell carcinoma). Please use sun protection </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before 
taking this medicine. </p>
<p>Tests and check-ups before and during treatment<br />
Laboratory tests may show lymphocytosis, an increase in white blood cells (lymphocytes) in your 
blood in the first few weeks of treatment. This is expected and may last for a few months. This does 
not necessarily mean that your blood cancer is getting worse. Your doctor will check your blood 
counts before and during the treatment and in rare cases the doctor may give you another medicine. 
Talk to your doctor about what your test results mean. 
Tumour lysis syndrome (TLS): Unusual levels of chemicals in the blood caused by the fast 
breakdown of cancer cells have occurred during treatment of cancer and sometimes even without 
treatment. This may lead to changes in kidney function, abnormal heartbeat, or seizures. Your doctor 
or another healthcare provider may do blood tests to check for TLS. 
Children and adolescents </p>
<p>BRUKINSA should not be used in children and adolescents, because it is unlikely to work.  </p>
<p>Other medicines and BRUKINSA </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This includes medicines obtained without a prescription, herbal medicines and 
supplements. This is because BRUKINSA may affect the way some medicines work. Also, some 
medicines can affect the way BRUKINSA works. </p>
<p>BRUKINSA may make you bleed more easily. This means you should tell your doctor if you take 
other medicines that increase your risk of bleeding. This includes medicines such as: 
* acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatories (NSAIDs) such as 
ibuprofen and naproxen, 
* anticoagulants such as warfarin, heparin and other medicines for treating or preventing blood 
clots, 
* supplements that may increase your risk of bleeding such as fish oil, vitamin E or flaxseed. </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before 
taking BRUKINSA. </p>
<p>Also tell your doctor if you take any of the following medicines   The effects of BRUKINSA 
or other medicines may be influenced if you take BRUKINSA together with any of the following 
medicines: 
* antibiotics to treat bacterial infections   ciprofloxacin, clarithromycin, 
erythromycin, nafcillin or rifampicin 
* medicines for fungal infections   fluconazole, itraconazole, ketoconazole, 
posaconazole, voriconazole 
* medicines for HIV infection   efavirenz, etravirine, indinavir, lopinavir, ritonavir, telaprevir 
* medicine to prevent nausea and vomiting associated with chemotherapy - aprepitant 
* medicines for depression   fluvoxamine, St. John s wort 
* medicine called kinase inhibitors for treatment of other cancers   imatinib 
* medicines for high blood pressure or chest pain   bosentan, diltiazem, verapamil<br />
<em> heart medicines/anti-arrhythmics   digoxin, dronedarone, quinidine<br />
</em> medicines to prevent seizures, to treat epilepsy, or to treat a painful condition of the face 
called trigeminal neuralgia   carbamazepine, mephenytoin, phenytoin<br />
* medicines for migraines and cluster headaches - dihydroergotamine, ergotamine 
* medicine for extreme sleepiness and other sleep problems - modafinil 
* medicine for psychosis and Tourette disorder - pimozide 
* medicines for anaesthesia   alfentanil, fentanyl 
* medicines called immunosuppressive agents   ciclosporin, sirolimus, tacrolimus </p>
<p>BRUKINSA with food </p>
<p>Grapefruit or Seville oranges (bitter oranges) should be consumed with caution around the time 
you take BRUKINSA. This is because they can increase the amount of BRUKINSA in your 
blood. </p>
<p>Pregnancy and breast-feeding  </p>
<p>Do not get pregnant while you are taking this medicine. BRUKINSA should not be used during 
pregnancy. It is not known if BRUKINSA will harm your unborn baby. </p>
<p>Women of childbearing age must use a highly effective method of birth control during treatment with 
BRUKINSA and for least one month after treatment. A barrier method of contraception (e.g., 
condoms) must be used with hormonal contraceptives such as birth control pills or devices.  </p>
<ul>
<li>Tell your doctor immediately if you become pregnant. </li>
<li>Do not breast-feed while you are taking this medicine. BRUKINSA may pass into breast milk. </li>
</ul>
<p>Driving and using machines  </p>
<p>You may feel tired or dizzy after taking BRUKINSA, which may affect your ability to drive or use 
machines. </p>
<p>BRUKINSA contains sodium  </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free .  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 320 mg (4 capsules) each day, either as 4 capsules once daily or 2 capsules 
in the morning and 2 in the evening. 
Your doctor may adjust the dose. 
Take the capsules by mouth with a glass of water with food or between meals. 
Take the capsules about the same time each day. 
BRUKINSA works best when it is swallowed whole. Therefore, swallow the capsules whole. Do not 
open, break or chew them. </p>
<p>If you take more BRUKINSA than you should  </p>
<p>If you take more BRUKINSA than you should, talk to a doctor straight away. Take the capsule 
packet and this leaflet with you. </p>
<p>If you forget to take BRUKINSA  </p>
<p>If you miss a dose, take it at the next scheduled time with a return to the normal schedule. If you take 
BRUKINSA once per day, take your next dose the following day. If you take the medicine twice a 
day, in the morning and in the evening and you forgot to take it in the morning, take your next dose in 
the evening. Do not take a double dose to make up for a forgotten dose. If you are not sure, talk to 
your doctor, pharmacist or nurse about when to take your next dose. </p>
<p>If you stop taking BRUKINSA  </p>
<p>Do not stop taking this medicine unless your doctor tells you. 
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Stop taking BRUKINSA and tell a doctor straight away if you notice any of the following 
side effects:<br />
* itchy bumpy rash, difficulty breathing, swelling of your face, lips, tongue or throat   you may 
be having an allergic reaction to the medicine. </p>
<p>Tell a doctor straight away if you notice any of the following side effects:  </p>
<p>Very common (may affect more than 1 in 10 people): 
* fever, chills, body aches, feeling tired, cold or flu symptoms, being short of breath, frequent 
and painful urination   these could be signs of an infection (viral, bacterial or fungal). These 
could include infections of the nose, sinus or throat (upper respiratory tract infection), 
pneumonia, or urinary tract. 
* bruising or increased tendency of bruising; contusions 
* bleeding 
* muscle and bone aches 
* skin rash 
* infection of the lung (lower respiratory tract infection)<br />
* dizziness 
* diarrhoea; your doctor may need to give you a fluid and salt replacement or another medicine 
* cough 
* fatigue 
* high blood pressure 
* constipation 
* Dizziness 
* blood in urine 
* blood tests showing a reduced number of blood cells. Your doctor should do blood tests during 
treatment with BRUKINSA to check the number of your blood cells. </p>
<p>Common (may affect up to 1 in 10 people): 
* swollen hands, ankles or feet 
* nosebleed 
* itching of the skin 
* small bleeding spots under the skin<br />
* fast heart rate, missed heart beats, weak or uneven pulse, lightheadedness, shortness of 
breath, chest discomfort (symptoms of heart rhythm problems) 
* weakness 
* low white blood cell count with fever (febrile neutropenia) </p>
<p>Uncommon (may affect up to 1 in 100 people): 
* reactivation of hepatitis B (if you had experienced hepatitis B, it may come back) 
* intestinal bleeding (blood in stool) 
* unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have 
occurred during treatment of cancer and sometimes even without treatment (tumour lysis 
syndrome) </p>
<p>Unknown: 
* redness and shedding of skin over a large area of the body, which may be itchy or painful 
(exfoliative dermatitis generalized) </p>
<p>Reporting of side effects  </p>
<p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What BRUKINSA contains  </p>
<ul>
<li>The active substance is zanubrutinib. Each hard capsule contains 80 mg of zanubrutinib.  </li>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>capsule content: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate 
(E487), silica colloidal anhydrous and magnesium stearate. See section 2  BRUKINSA 
contains sodium . </p>
</li>
<li>capsule shell: gelatin and titanium dioxide (E171) </li>
<li>printing ink: shellac glaze (E904), iron oxide black (E172) and propylene glycol (E1520). </li>
</ul>
<p>What BRUKINSA looks like and contents of the pack </p>
<p>BRUKINSA is a white to off-white hard capsule of 22 mm in length, marked with  ZANU 80  in 
black ink on one side.<br />
The capsules are provided in a plastic bottle with a child resistant closure. Each bottle contains 
120 hard capsules. </p>
<p>Marketing Authorisation Holder </p>
<p>BeiGene Ireland Ltd. 
10 Earlsfort Terrace 
Dublin 2 
D02 TIreland 
Tel. 
+353 1 566 7E-mail  bg.ireland@beigene.com  </p>
<p>Manufacturer </p>
<p>BeiGene Switzerland GmbH   Dutch Branch 
Evert van de Beekstraat 1, 1118 CL Schiphol 
The Netherlands </p>
<p>BeiGene Germany GmbH 
Georges-K hler-Str. 2 
79539 L rrach, 
Germany </p>
<p>BeiGene Netherlands B.V. 
Evert van de Beekstraat 1, 1118 CL Schiphol 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
BeiGene Belgium SRL 
T l/Tel: 0800 774 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD<br />
Te .: +359 (0)2 4942 Luxembourg/Luxemburg 
BeiGene France sarl 
T l/Tel: 0800 85 esk  republika 
Swixx Biopharma s.r.o. 
Tel: +420 242 434 Magyarorsz g 
Swixx Biopharma Kft. 
Tel.: +36 1 9206 Danmark 
BeiGene Sweden AB 
Tlf: 808 10 Malta 
Swixx Biopharma S.M.S.A. 
Tel: +30 214 444 9Deutschland 
Beigene Germany GmbH 
Tel: 0800 200 8Nederland 
BeiGene Netherlands B.V. 
Tel: 08000 233 Eesti 
Swixx Biopharma O <br />
Tel: +372 640 1Norge 
BeiGene Sweden AB 
Tlf: 800 31 <br />
Swixx Biopharma  . .<br />
Tel: +30 214 444 9 sterreich 
BeiGene Austria GmbH 
Tel: 0800 909 Espa a 
BeiGene Spain, SLU 
Tel: 9000 31 Polska 
BeiGene Poland sp. z o. o. 
Tel.: 8000 80 France 
BeiGene France sarl 
T l: 080 554 3Portugal 
BeiGene Portugal, Unipessoal Lda 
Tel: 800 210 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Ireland 
BeiGene UK Ltd 
Tel: 1800 812 Rom nia 
Swixx Biopharma S.R.L 
Tel: +40 37 1530 Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 2355  sland 
BeiGene Sweden AB 
S mi: 800 4Slovensk  republika 
Swixx Biopharma s.r.o.<br />
Tel: +421 2 20833 Italia 
BeiGene Italy Srl 
Tel: 800 588 Suomi/Finland 
BeiGene Sweden AB 
Puh/Tel: 0800 774 <br />
Swixx Biopharma  . .<br />
Tel: +30 214 444 9Sverige 
BeiGene Sweden AB 
Puh/Tel: 0200 810 Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47 Northern Ireland 
BeiGene UK Ltd 
Tel: 0800 917 6This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-c2d0e28fbe1723337dab22fe407d0234
InstanceOf: CompositionUvEpi
Title: "Composition for brukinsa Package Leaflet"
Description:  "Composition for brukinsa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp24f578d462a457567344326b7c54ba53)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - brukinsa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage BRUKINSA 
3. Sådan skal du tage BRUKINSA 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What brukinsa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What brukinsa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>BRUKINSA er et lægemiddel mod kræft, som indeholder det aktive stof zanubrutinib. Det tilhører en 
klasse af lægemidler, der kaldes proteinkinasehæmmere. Dette lægemiddel virker ved at blokere 
Brutons tyrosinkinase, et protein i kroppen, der hjælper disse kræftceller med at vokse og overleve. 
Ved at blokere dette protein hjælper BRUKINSA med at reducere antallet af kræftceller. Det hæmmer 
også udviklingen af kræftsygdommen. </p>
<p>BRUKINSA anvendes til at behandle Waldenstrøms makroglobulinæmi (også kaldet 
lymfoplasmacytisk lymfom). Det er en kræft, der påvirker en type hvide blodlegemer kaldet B-
lymfocytter, der producerer for meget af et protein kaldet IgM.  </p>
<p>Denne medicin bruges, når sygdommen er kommet tilbage, eller behandlingen ikke har fungeret, eller 
hos patienter, der ikke kan få kemoterapi sammen med et antistof. </p>
<p>BRUKINSA bruges også til behandling af marginal zone lymfom. Dette er en type kræft, der også 
påvirker B-lymfocytter eller B-celler. Ved marginal zone lymfom formerer de unormale B-celler sig 
for hurtigt og lever for længe. Dette kan forårsage forstørrelse af organer, der er en del af kroppens 
naturlige forsvar, såsom lymfeknuder og milt. De unormale B-celler kan også påvirke forskellige 
organer, såsom mave, spytkirtel, skjoldbruskkirtel, øjne, lunger, knoglemarv og blod. Patienterne kan 
have feber, vægttab, træthed og svedeture om natten, men også symptomer, der afhænger af, hvor 
lymfomet udvikler sig. Denne medicin bruges, når sygdommen er vendt tilbage, eller behandlingen 
ikke har fungeret. </p>
<p>BRUKINSA bruges også til behandling af kronisk lymfatisk leukæmi (CLL), en anden type kræft, der 
rammer B-celler, og som involverer lymfeknuderne. Denne medicin anvendes til patienter, der ikke 
tidligere er blevet behandlet for CLL, eller når sygdommen er kommet tilbage eller ikke har reageret 
på tidligere behandling. </p>
<p>BRUKINSA bruges også til behandling af follikulært lymfom (FL). FL er en langsomt voksende 
kræftsygdom, der påvirker B-lymfocytterne. Hvis man har FL, har man for mange af disse B-
lymfocytter i sine lymfeknuder, milt og knoglemarv. BRUKINSA tages sammen med et andet 
lægemiddel kaldet 'obinutuzumab', når sygdommen er vendt tilbage, eller når tidligere anvendt 
medicin ikke har været effektiv. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke BRUKINSA 
hvis du er allergisk over for zanubrutinib eller et af de øvrige indholdsstoffer i lægemidlet (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager BRUKINSA: </p>
<ul>
<li>
<p>hvis du nogensinde har haft usædvanlige blå mærker eller blødning, eller hvis du tager andre 
lægemidler eller kosttilskud, der øger din risiko for blødning (Se punktet "Brug af anden 
medicin sammen med BRUKINSA"). Hvis du for nylig er blevet opereret, eller der er 
planlagt operation for dig, kan din læge bede dig om at stoppe med at tage BRUKINSA i kort 
tid (3-7 dage) før og efter operationen eller tandlægeindgrebet </p>
</li>
<li>
<p>hvis du har uregelmæssige hjerteslag eller tidligere har haft uregelmæssige hjerteslag eller 
alvorligt hjertesvigt, eller hvis du oplever noget af det følgende: åndenød, svaghed, uklarhed, 
besvimelse eller nær-besvimelse, smerter i brystet eller hævede ben </p>
</li>
<li>
<p>hvis du nogen sinde er blevet gjort opmærksom på, at du har højere risiko for infektioner. Du 
kan få virus-, bakterie- eller svampeinfektioner under behandling med BRUKINSA med 
følgende mulige symptomer: feber, kulderystelser, svaghed, forvirring, kropssmerter, 
forkølelses- eller influenzasymptomer, føle dig træt eller åndenød, gulfarvning af huden eller 
øjnene (gulsot). </p>
</li>
<li>
<p>hvis du nogensinde har haft eller muligvis har hepatitis B. Dette skyldes, at BRUKINSA kan 
reaktivere hepatitis B-virus. Patienterne vil blive undersøgt nøje af deres læge for tegn på 
denne infektion, før behandling startes </p>
</li>
<li>
<p>hvis du har lever- eller nyreproblemer </p>
</li>
<li>
<p>hvis du for nylig er blevet opereret, specielt hvis det kan påvirke, hvordan din mave eller dine 
tarme absorberer mad eller medicin </p>
</li>
<li>
<p>hvis du for nylig havde et lavt antal røde blodlegemer, infektionsbekæmpende celler eller 
blodplader i blodet </p>
</li>
<li>
<p>hvis du tidligere har haft andre karcinomer, herunder hudkræft (f.eks. basalcellekræft eller 
pladeepitelkræft). Sørg for at beskytte dig mod solen </p>
</li>
</ul>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager dette lægemiddel, hvis noget af 
ovenstående gælder for dig (eller hvis du er i tvivl). </p>
<p>Undersøgelser og kontrol før og under behandling 
Laboratorietests kan vise lymfocytose, en stigning i hvide blodlegemer (lymfocytter) i dit blod i de 
første par uger af behandlingen. Dette er forventeligt og kan vare et par måneder. Det betyder ikke 
nødvendigvis, at din blodkræft bliver værre. Din læge vil undersøge dit blodtal før og under 
behandlingen, og i sjældne tilfælde kan lægen blive nødt til at give dig anden medicin. Din læge vil 
fortælle dig, hvad dine testresultater betyder. </p>
<p>Tumorlysissyndrom (TLS): Usædvanlige niveauer af kemikalier i blodet forårsaget af hurtig 
nedbrydning af kræftceller er sket under behandling af kræft og nogle gange endda uden behandling. 
Dette kan føre til ændringer i nyrefunktionen, unormal hjerterytme eller anfald. Din læge eller en 
anden sundhedsudbyder kan tage blodprøver for at tjekke for TLS. </p>
<p>Børn og unge 
BRUKINSA bør ikke anvendes til børn og unge, da det er usandsynligt at det ville kunne fungere. </p>
<p>Brug af anden medicin sammen med BRUKINSA 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Det gælder også håndkøbsmedicin, 
naturlægemidler og kosttilskud. Dette skyldes, at BRUKINSA kan påvirke den måde, lægemidler 
virker på. Nogle lægemidler kan også påvirke den måde, BRUKINSA virker på. </p>
<p>BRUKINSA kan gøre dig tilbøjelig til at bløde lettere. Det betyder, at du skal fortælle din læge, 
hvis du tager anden medicin, som kan øge din risiko for blødning. Dette inkluderer lægemidler 
såsom: </p>
<ul>
<li>
<p>acetylsalicylsyre (aspirin) og non-steroide anti-inflammatoriske midler (NSAID'er), såsom 
ibuprofen og naproxen, </p>
</li>
<li>
<p>antikoagulanter såsom warfarin, heparin eller andre midler til behandling eller forebyggelse af 
blodpropper, </p>
</li>
<li>
<p>kosttilskud, som kan øge din risiko for blødning, såsom fiskeolie, vitamin E eller hørfrø. </p>
</li>
</ul>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager BRUKINSA, hvis noget af 
ovenstående gælder for dig (eller hvis du er i tvivl). </p>
<p>Fortæl også din læge, hvis du tager et af følgende lægemidler - virkningerne af BRUKINSA eller 
anden medicin kan blive påvirket, hvis du tager BRUKINSA sammen med en af følgende lægemidler: </p>
<ul>
<li>
<p>antibiotika til behandling af bakterielle infektioner - ciprofloxacin, clarithromycin, 
erythromycin, nafcillin eller rifampicin </p>
</li>
<li>
<p>medicin mod svampeinfektioner - fluconazol, itraconazol, ketoconazol, posaconazol, 
voriconazol </p>
</li>
<li>
<p>medicin mod hiv-infektion - efavirenz, etravirin, indinavir, lopinavir, ritonavir, telaprevir </p>
</li>
<li>
<p>medicin til forebyggelse af kvalme og opkast i forbindelse med kemoterapi - aprepitant </p>
</li>
<li>
<p>medicin mod depression - fluvoxamin, perikon </p>
</li>
<li>
<p>medicin kaldet kinasehæmmere til behandling af andre kræftformer - imatinib </p>
</li>
<li>
<p>medicin mod forhøjet blodtryk eller smerter i brystet - bosentan, diltiazem, verapamil </p>
</li>
<li>
<p>hjertemedicin/antiarytmika - digoxin, dronedaron, kinidin </p>
</li>
<li>
<p>medicin til forebyggelse af anfald, til behandling af epilepsi eller til behandling af en smertefuld 
tilstand i ansigtet kaldet trigeminusneuralgi - carbamazepin, mephenytoin, phenytoin </p>
</li>
<li>
<p>medicin mod migræne og klyngehovedpine - dihydroergotamin, ergotamin </p>
</li>
<li>
<p>medicin mod ekstrem søvnighed og andre søvnproblemer - modafinil </p>
</li>
<li>
<p>medicin mod psykose og Tourettes lidelse - pimozid </p>
</li>
<li>
<p>medicin til anæstesi - alfentanil, fentanyl </p>
</li>
<li>
<p>medicin, der kaldes immunsuppressive midler - ciclosporin, sirolimus, tacrolimus </p>
</li>
</ul>
<p>BRUKINSA med mad 
Grapefrugt eller pomerans (bitre appelsiner) skal indtages med forsigtighed omkring  det tidspunkt, du 
tager BRUKINSA. Dette skyldes, at de kan øge mængden af BRUKINSA i dit blod. </p>
<p>Graviditet og amning 
Du må ikke blive gravid, mens du tager dette lægemiddel. BRUKINSA må ikke anvendes under 
graviditet. Det vides ikke, om BRUKINSA vil skade dit ufødte barn. </p>
<p>Fertile kvinder skal anvende en højeffektiv præventionsmetode under behandling med BRUKINSA og 
i mindst en måned efter behandlingen. En barrieremetode (f.eks. kondomer) skal bruges sammen med 
hormonelle præventionsmidler, som f.eks. p-piller, p-sprøjte eller p-stav. </p>
<ul>
<li>
<p>Fortæl det straks til lægen, hvis du bliver gravid. </p>
</li>
<li>
<p>Du må ikke amme, mens du tager dette lægemiddel. BRUKSINA kan overføres til 
modermælken. </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed 
Du kan føle dig træt eller svimmel, når du har taget BRUKINSA, og det kan påvirke din evne til at 
føre motorkøretøjer og betjene værktøjer og maskiner. </p>
<p>BRUKINSA indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 320 mg(4 kapsler) hver dag, enten som 4 kapsler én gang dagligt 
eller 2 kapsler om morgenen og 2 om aftenen. </p>
<p>Din læge vil muligvis justere dosen. 
Kapslerne skal tages gennem munden med et glas vand sammen med mad eller mellem måltider. 
Kapslerne skal tages på cirka samme tidspunkt hver dag. 
BRUKINSA virker bedst, når den synkes hele. Synk derfor kapslerne hel. De må ikke åbnes, brækkes 
eller tygges. </p>
<p>Hvis du har taget for meget BRUKINSA 
Kontakt straks en læge, hvis du har taget for meget BRUKINSA. Medbring kapselpakken og denne 
indlægsseddel. </p>
<p>Hvis du har glemt at tage BRUKINSA 
Hvis du glemmer en dosis, skal du tage den på det næste planlagte tidspunkt og derefter vende tilbage 
til den normale tidsplan. Hvis du tager BRUKINSA en gang dagligt, skal du tage din næste dosis den 
følgende dag. Hvis du tager medicinen to gange om dagen, om morgenen og om aftenen, og du har 
glemt at tage den om morgenen, skal du tage din næste dosis om aftenen. Du må ikke tage en 
dobbeltdosis som erstatning for den glemte kapsel. Spørg lægen, apotekspersonalet eller 
sygeplejersken, hvis du er i tvivl om, hvornår du skal tage din næste dosis. </p>
<p>Hvis du holder op med at tage BRUKINSA 
Du må ikke stoppe med at tage dette lægemiddel, medmindre lægen siger, du skal. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Stop med at tage BRUKINSA, og søg straks lægehjælp, hvis du bemærker en eller flere af 
følgende bivirkninger: </p>
<ul>
<li>kløende, ujævnt udslæt, vejrtrækningsbesvær, hævelse af ansigt, læber, tunge eller hals - du 
kan have en allergisk reaktion på lægemidlet. </li>
</ul>
<p>Søg straks læge, hvis du oplever en eller flere af følgende bivirkninger: </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer): </p>
<ul>
<li>feber, kulderystelser, kropssmerter, træthed, forkølelses- eller influenzasymptomer, åndenød, 
hyppig og smertefuld vandladning - dette kan være tegn på en infektion (virus-, bakterie- eller  </li>
</ul>
<p>svampeinfektion). Det kan dreje sig om infektioner i næsen, bihulerne eller halsen (infektion i 
de øvre luftveje), lungebetændelse eller urinvejsinfektion. </p>
<ul>
<li>
<p>blodudtrædninger eller øget tilbøjelighed til blodudtrædninger, blå mærker </p>
</li>
<li>
<p>blødning </p>
</li>
<li>
<p>ømme muskler og knogler </p>
</li>
<li>
<p>hududslæt </p>
</li>
<li>
<p>infektion i lungerne (infektion i de nedre luftveje) </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>diarré, din læge bliver muligvis nødt til at give dig væske og salterstatning eller et andet 
lægemiddel </p>
</li>
<li>
<p>hoste </p>
</li>
<li>
<p>træthed </p>
</li>
<li>
<p>højt blodtryk </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>blod i urinen </p>
</li>
<li>
<p>blodprøver viser et reduceret antal blodlegemer. Din læge vil tage blodprøver under behandling 
med BRUKINSA for at kontrollere antallet af dine blodlegemer. </p>
</li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>hævede hænder, ankler eller fødder </p>
</li>
<li>
<p>næseblod </p>
</li>
<li>
<p>hudkløe </p>
</li>
<li>
<p>små blødende pletter under huden  </p>
</li>
<li>
<p>hurtig hjertefrekvens, oversprunget hjerteslag, svag eller ujævn puls, følelse af at være uklar, 
kortåndethed, ubehag i brystet (symptomer på hjerterytmeproblemer) </p>
</li>
<li>
<p>svaghed </p>
</li>
<li>
<p>lavt antal hvide blodlegemer med feber (febril neutropeni) </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer): </p>
<ul>
<li>
<p>reaktivering af hepatitis B (hvis du tidligere har haft hepatitis B, kan sygdommen komme igen) </p>
</li>
<li>
<p>blødning i tarmene (blod i afføringen) </p>
</li>
<li>
<p>usædvanlige niveauer af kemikalier i blodet forårsaget af den hurtige nedbrydning af 
kræftceller er sket under behandling af kræft og nogle gange endda uden behandling 
(tumorlysesyndrom) </p>
</li>
</ul>
<p>Ikke kendt:  </p>
<ul>
<li>Rødme og afskalning af huden over et stort område af kroppen, som kan være kløende eller 
smertefuldt (generaliseret eksfoliativ dermatitis) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store brukinsa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store brukinsa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og beholderen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. </p>
<p>Du må ikke bortskaffe medicin via afløbet eller sammen med husholdningsaffald. Spørg 
apotekspersonalet, hvordan du skal bortskaffe medicinrester. Dette vil hjælpe til beskyttelse af miljøet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>BRUKINSA indeholder  </p>
<ul>
<li>
<p>Aktivt stof/aktive stoffer: zanubrutinib. Hver kapsel, hård, indeholder 80 mg zanubrutinib. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>kapselindhold: mikrokrystallinsk cellulose, croscarmellosenatrium, natriumlaurylsulfat (E487), 
kolloid vandfri silica, magnesiumstearat (se pkt. 2 “BRUKINSA indeholder natrium"). </p>
</li>
<li>kapselskal: gelatine og titandioxid (E171) </li>
<li>trykfarve: shellak (E904), sort jernoxid (E172) og propylenglykol (E1520). </li>
</ul>
<p>Udseende og pakningsstørrelser 
BRUKINSA er en hvid til offwhite, hård kapsel med "ZANU 80" påtrykt med sort blæk på den ene 
side. Kapslerne leveres i en plastbeholder med børnesikret lukning. Hver beholder 
indeholder 60 eller 120 kapsler, hårde. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>BeiGene Ireland Ltd. 
10 Earlsfort Terrace 
Dublin 2 
D02 TIrland 
Tlf. 
 +353 1 566 7E-mail  bg.ireland@beigene.com  </p>
<p>Fremstiller </p>
<p>BeiGene Switzerland GmbH - Dutch Branch 
Evert van de Beekstraat 1, 1118 CL Schiphol, Holland </p>
<p>BeiGene Germany GmbH 
Georges-Köhler-Str. 2, 79539 Lörrach, Tyskland </p>
<p>BeiGene Netherlands B.V. 
Evert van de Beekstraat 1, 1118 CL Schiphol, Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen : </p>
<p>België/Belgique/Belgien 
BeiGene Belgium SRL 
Tél/Tel: 0800 774<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD<br />
Luxembourg/Luxemburg 
BeiGene France sarl </p>
<p>Teл.: +359 (0)2 4942<br />
Tél/Tel: 0800 85 
Česká republika 
Swixx Biopharma s.r.o. 
Tel: +420 242 434<br />
Magyarország 
Swixx Biopharma Kft. 
Tel.: +36 1 9206<br />
Danmark 
BeiGene Sweden AB 
Tlf: 80 81 06<br />
Malta 
Swixx Biopharma S.M.S.A. 
Tel: +30 214 444 9 
Deutschland 
Beigene Germany GmbH 
Tel: 0800 200 8 
Nederland 
BeiGene Netherlands B.V. 
Tel: 08000 233<br />
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 1 
Norge 
BeiGene Sweden AB 
Tlf: 800 31<br />
Ελλάδα 
Swixx Biopharma Μ.Α.Ε 
Τηλ: +30 214 444 9 
Österreich 
BeiGene Austria GmbH 
Tel: 0800 909 España 
BeiGene Spain, SLU 
Tel: 9000 31<br />
Polska 
BeiGene Poland sp. z o. o. 
Tel.: 8000 80<br />
France 
BeiGene France sarl 
Tél: 080 554 3 
Portugal 
BeiGene Portugal, Unipessoal Lda 
Tel: 800 210<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
Ireland 
BeiGene UK Ltd 
Tel: 1800 812<br />
România 
Swixx Biopharma S.R.L 
Tel: +40 37 1530<br />
Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 2355<br />
Ísland 
BeiGene Sweden AB 
Sími: 800 4 
Slovenská republika 
Swixx Biopharma s.r.o.<br />
Tel: +421 2 20833<br />
Italia 
BeiGene Italy Srl 
Tel: 800 588<br />
Suomi/Finland 
BeiGene Sweden AB 
Puh/Tel: 0800 774<br />
Κύπρος 
Swixx Biopharma Μ.Α.Ε 
Τηλ: +30 214 444 9 
Sverige 
BeiGene Sweden AB 
Puh/Tel: 0200 810<br />
Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47 United Kingdom (Northern Ireland) 
BeiGene UK Ltd 
Tel: 0800 917 6 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-c2d0e28fbe1723337dab22fe407d0234
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for brukinsa Package Leaflet for language en"
Description: "ePI document Bundle for brukinsa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-c2d0e28fbe1723337dab22fe407d0234"
* entry[0].resource = composition-en-c2d0e28fbe1723337dab22fe407d0234

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc2d0e28fbe1723337dab22fe407d0234"
* entry[=].resource = mpc2d0e28fbe1723337dab22fe407d0234
                            
                    
Instance: bundlepackageleaflet-da-c2d0e28fbe1723337dab22fe407d0234
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for brukinsa Package Leaflet for language da"
Description: "ePI document Bundle for brukinsa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-c2d0e28fbe1723337dab22fe407d0234"
* entry[0].resource = composition-da-c2d0e28fbe1723337dab22fe407d0234

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc2d0e28fbe1723337dab22fe407d0234"
* entry[=].resource = mpc2d0e28fbe1723337dab22fe407d0234
                            
                    



Instance: mpc2d0e28fbe1723337dab22fe407d0234
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product BRUKINSA 80 mg hard capsules"
Description: "BRUKINSA 80 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1576/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "BRUKINSA 80 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: c2d0e28fbe1723337dab22fe407d0234ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "brukinsa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with brukinsa"

* subject = Reference(mp24f578d462a457567344326b7c54ba53)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#brukinsa "brukinsa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-c2d0e28fbe1723337dab22fe407d0234) // brukinsa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-c2d0e28fbe1723337dab22fe407d0234) // brukinsa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-c2d0e28fbe1723337dab22fe407d0234
InstanceOf: List

* insert c2d0e28fbe1723337dab22fe407d0234ListRuleset
    